Bespoke Data Research Services for CROs, in an Era of Precision Medicine
Published on: 29 Sept 2025
Last updated: 29 Sept 2025
Listen to audio summary of this article
In the complex, high-stakes world of clinical research, data is the most valuable currency. For Contract Research Organizations (CROs), which manage clinical trials for pharmaceutical, biotechnology, and medical device companies, the ability to access, analyse, and leverage high-quality data is paramount.
While CROs have historically focused on managing clinical operations and regulatory compliance, their role is rapidly evolving into one of advanced data strategists. The shift is driven by the increasing complexity of clinical trials, the explosion of data from diverse sources (e.g., electronic health records, genomics, and real-world data), and the industry-wide push toward personalised, patient-centric medicine.
Generic, off-the-shelf data sets are no longer sufficient to meet these demands. This has created a critical need for bespoke, customised data research services—a niche where specialised B2B data providers are carving out a significant advantage.
By providing tailor-made, human-verified secondary data, these data partners empower CROs to overcome persistent challenges in patient recruitment, site feasibility, and market access, ultimately accelerating the drug development pipeline.
This article explores the growing necessity of bespoke data research, delves into the specific challenges CROs face, and outlines how customised secondary data is revolutionising clinical trial strategy.
The rising tide of complexity: Why CROs need a new data strategy
The clinical research landscape has undergone a dramatic transformation. Trials are no longer simple, large-scale endeavors focused on broad populations. Instead, they are increasingly targeted, with complex protocols focusing on smaller, more specific patient subgroups, particularly in therapeutic areas like oncology and rare diseases. This evolution brings a host of data-related challenges for CROs:
Patient recruitment and retention: Finding and enrolling the right patient population is a persistent and costly bottleneck in clinical trials. For rare diseases, this challenge is even more acute, requiring a deep, nuanced understanding of specific patient demographics, disease prevalence, and location. Generic data lists often lack the granularity to effectively target these niche populations.
Site feasibility: Selecting optimal clinical trial sites is a crucial early step, and poor site selection can lead to significant delays and budget overruns. Standardised databases may provide a list of potential sites, but they rarely offer the deep, contextual intelligence needed to assess a site's actual patient population, investigator experience, and operational capacity for a specific protocol.
Access to real-world data (RWD): The use of RWD—data collected outside of a traditional clinical trial setting—is crucial for understanding disease progression, informing trial design, and supporting regulatory submissions. However, accessing and integrating this diverse data from sources like electronic health records (EHRs), claims data, and patient registries can be a major technological and logistical hurdle.
Competitive intelligence and market access: As the market becomes more crowded, CROs and their sponsors need detailed, up-to-date competitive intelligence. Standard data reports often fail to capture the real-time changes in trial landscapes, regulatory movements, or competitor activities that can provide a strategic advantage.
Data quality and integrity: Clinical data comes in many different formats and from many different systems, leading to inconsistencies and quality issues that can compromise the integrity of a trial. Manual data cleaning is time-consuming and prone to errors, especially when dealing with unstructured data.
Ascentrik Research and the Bespoke Advantage
This is where a specialised provider of bespoke data research, such as Ascentrik Research, offers a transformative solution. Unlike vendors that rely on automated scraping or offer standardised, potentially stale data sets, Ascentrik specialises in building customised data, meticulously sourced and verified by a dedicated team of full-time researchers.
This human-driven approach is the key differentiator, ensuring that the data is not only current but also precisely aligned with a CRO's unique needs.
The services provided go beyond simple data delivery and are deeply integrated into the CRO's strategic workflow:
Customised patient and site identification: For patient recruitment, Ascentrik can build highly specific datasets that identify not just potential trial participants but also the physicians and clinics that specialise in treating those populations. This human-verified data goes beyond generic demographics to include granular details that inform a precise and effective recruitment strategy.
Enhanced clinical trial feasibility: In a crowded clinical trial landscape, understanding the nuances of a potential trial site is invaluable. Bespoke data research can provide in-depth profiles of clinical sites, including their historical performance, investigator experience, and access to specific patient populations. This level of customised intelligence empowers CROs to make more informed decisions about site selection, minimising risk and maximising the chances of on-time enrollment.
Competitive and market intelligence: To support their clients' strategic goals, CROs need a clear picture of the competitive landscape. Ascentrik can provide detailed intelligence on competitor pipelines, clinical trial activity, regulatory approvals, and market trends. By delivering actionable insights on sales triggers and key business activities, bespoke data research helps CROs and their clients stay ahead of the curve.
Real-world data (RWD) sourcing and enrichment: While much RWD is available in public or purchased datasets, it is often unstructured and incomplete. Bespoke research can be used to source specific, supplementary RWD and enrich existing data with additional, human-verified insights. This can significantly improve the accuracy and relevance of RWD analyses, especially in a time when regulatory bodies are increasingly accepting RWD to support market authorisation.
The power of human-verified secondary data
The term "secondary data" often conjures images of static, public-domain information. However, bespoke secondary data research elevates this concept entirely. Ascentrik's approach highlights the key distinctions:
Freshness and relevance: The use of full-time researchers ensures that data is actively sourced, verified, and updated, providing clients with intelligence that is far fresher and more relevant than standard datasets.
Precision over volume: While big data is often about quantity, bespoke data is about quality and precision. By focusing on building data tailored to a specific research question, bespoke services deliver a much higher return on investment than a one-size-fits-all approach.
Trust and accuracy: The human-driven verification process, combined with rigorous quality checks and open communication with clients, builds a level of trust that automated solutions cannot match. This accuracy is critical in the heavily regulated life sciences and healthcare sectors.
The Future of Bespoke Data Research for CROs
As the clinical research industry continues to evolve, the demand for sophisticated, customised data will only grow. The market for CRO services is projected to expand significantly, and a major driver of that growth is the increasing need for specialised data services, specially in relation to AI and RWD.
Looking ahead, bespoke data research services will become even more integral to the CRO value proposition. This will likely manifest in several ways:
Deeper integration with AI and ML: Bespoke, high-quality data will serve as the foundation for training more precise and effective machine learning models. CROs will rely on bespoke data providers to enrich their existing data and ensure that their AI models are built on accurate, relevant, and human-verified information.
Expansion into emerging markets: As CROs increasingly conduct trials in new geographies, they will need localised, custom data on healthcare systems, patient populations, and regulatory landscapes. Bespoke data research will provide the necessary intelligence to navigate these complexities.
Targeted support for decentralised clinical trials (DCTs): The rise of DCTs, which rely heavily on real-world data and digital patient engagement, creates a new set of data needs. Bespoke services can help identify and recruit patients in their local communities and provide granular data on patient outcomes outside of a traditional clinical setting.
For CROs operating in this dynamic environment, a partnership with a bespoke data research provider like Ascentrik Research is no longer a luxury but a strategic necessity. It is an investment in precision, speed, and competitive advantage, enabling CROs to move beyond being "bodies for hire" and solidify their role as essential partners in driving medical innovation. By leveraging high-quality, customised data, CROs can help bring life-saving therapies to market faster, more efficiently, and with greater confidence.
Table of Content
